AXIS Consulting and IPHA are organising a webinar on BeNeLuxAI: Recent Experiences & Important Learnings on 23rd September 2021. In addition to covering developments at BeNeLuxAI and the role of the pharmaceutical industry group in such collaborations, this webinar also provides an opportunity to hear about important updates on the International...
Like many parts of the world, market access is a crucial component of making sure the right treatment option is available to the right patient at the right time. In Ireland, we have a very unique process to determine whether or not a new medicine will be reimbursed. Such medicines...
AXIS Consulting’s recently published Irish Health and Market Access Landscape Report is featured in the August edition of Hospital Professional News (HPN). Read the full article here
AXIS Consulting is delighted to sponsor Session 2 of this year’s ABPI Annual Conference, “Building UK assets: Discovery, Data and Genomics.” We are particularly pleased to support this session which is highly topical for all stakeholders as we emerge from the COVID-19 pandemic. [...]
AXIS Consulting is excited to announce the confirmed speakers for its Spring Market Access Masterclass “Access to New Medicines in Ireland- What’s Changing? “With the ongoing Government restrictions, this event will take place as two half-day virtual events on 19th & 24th March from 9.00-12.30 pm. This exciting event will review...
AXIS is excited to announce that it is expanding its team of specialists to meet the growing business needs and now wishes to appoint a Senior Medical / Scientific Writer. This exciting role will offer the successful candidate the opportunity to join a fast-paced dynamic team which includes health economists,...
Access to New Medicines A look at Irish Reimbursement Timelines Research Poster Presentation: An Investigation into Factors Influencing Reimbursement Timelines of New Medicines in Ireland Authors: Cillian Copeland, Brenda Dooley, Marian Hernon, Marsha Tracey AXIS had the opportunity to present their research on the factors influencing reimbursement timelines of new medicines in Ireland at...
Market Access managers typically triage their approach to submissions to the UK and Ireland. Submissions to the National Institute for Health and Care Excellence (NICE) are the first priority – for good reason since NICE seeks to issue its guidance when the new medicine receives marketing authorisation. Next, companies usually...
09/10/2020 “The Value of Expert Opinion in Reimbursement applications” - For an insightful read on the importance of integrating Irish Expert Opinion into reimbursement applications, read this paper by Brenda Dooley, AXIS founder & CEO, recently published in CONNECT, the annual journal of the MRII. Here Brenda outlines how Expert...
02/09/2020 AXIS Consulting is delighted to announce the confirmed speakers for its 5th Market Access Masterclass. Keynote speakers on 18th September are Dr Valerie Walshe, Senior Health Economist and advisor on drug reimbursement, Health Service Executive who will discuss the funding of new medicines in Ireland and Mr. Philip Watt,...
